Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (DE:TE1)
FRANKFURT:TE1
Bio-Techne (TE1) Stock Price & Analysis
0 Followers
TE1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€49.27 - €80.22
Previous Close€58.5
Volume0.00
Average Volume (3M)2.00
Market Cap
€9.21B
Enterprise Value€9.60B
Total Cash (Recent Filing)$135.65M
Total Debt (Recent Filing)$555.70M
Price to Earnings (P/E)N/A
Beta0.65
Next Earnings
May 01, 2024EPS Estimate
€0.43Last Dividend Ex-Date
Feb 09, 2024Dividend Yield0.51%
Share Statistics
EPS (TTM)N/A
Shares Outstanding157,191,685
10 Day Avg. Volume0
30 Day Avg. Volume2
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)22.78
Price to Sales (P/S)8.16
Price to Cash Flow (P/CF)29.70
P/FCF Ratio34.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.39
Enterprise Value/Gross Profit12.48
Enterprise Value/Ebitda25.44
Forecast
1Y Price Target
€75.09Price Target Upside28.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bio-Techne News
Bulls Say, Bears Say
Bulls Say
Market RecoveryConsumables likely to recover first as biopharma funding recovery and China stabilization are observed.
Revenue GrowthRecurring revenue streams from companies like TECH, RVTY, and BIO are expected to benefit early from the biopharma sector's recovery.
Strategic InvestmentsInvestments in local China capacities are strategic moves to leverage long-term market recovery and opportunities.
Bears Say
Financial PerformanceAdjusted Gross Margin percentage declined significantly, impacting profitability.
Management ChangesThe departure of a long-time, trusted CEO raises concerns about future leadership and company direction.
Market PositionA notable decline in China revenue due to sustained low capital expenditure affects market share.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.10% Other Institutional Investors
98.90% Public Companies and
Individual Investors
TE1 FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was €49.27 and its highest was €80.22 in the past 12 months.
What is Bio-Techne’s market cap?
Currently, no data Available
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is May 01, 2024 which is in 4 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Feb 01, 2024. The company reported €0.377 earnings per share for the quarter, missing the consensus estimate of €0.388 by -€0.011.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of €0.07 which represents an annual dividend yield of 0.51%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is €0.43.
How many shares outstanding does Bio-Techne have?
Currently, no data Available
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of €0.377 in its last earnings report, missing expectations of €0.388. Following the earnings report the stock price went down -2.325%.
Which hedge fund is a major shareholder of Bio-Techne?
Among the largest hedge funds holding Bio-Techne’s share is Mairs & Power Inc. It holds Bio-Techne’s shares valued at 238M.
---
Bio-Techne Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€75.09 (28.37% Upside)
€75.09 (28.37% Upside)
Blogger Sentiment
Bullish
DE:TE1 Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $800.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.06%
12-Months-Change
Fundamentals
Return on Equity
11.82%
Trailing 12-Months
Asset Growth
15.54%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.
---
TE1 Earnings Call
Q2 2024
0:00 / 0:00
---
TE1 Net revenue Breakdown
74.40% Protein Sciences
25.74% Diagnostics and Genomics
---
TE1 Stock 12 Months Forecast
Average Price Target
€75.09
▲(28.37% Upside)
Technical Analysis
Best Analysts Covering TE1
1 Year
1 Year Success Rate
17/30 ratings generated profit
1 Year Average Return
+12.69%
reiterated a buy rating 3 months ago
Copying Catherine Ramsey Schulte's trades and holding each position for 1 Year would result in 56.67% of your transactions generating a profit, with an average return of +12.69% per trade.
---